Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Study: Collaborative care reduces anxiety and bolsters mother-baby bond

  Comprehensive strategies linking obstetrics and neonatology reduced maternal separation anxiety in families affected by FNAIT.

• Survey: Doctors agree on FNAIT treatment methods but differ on timing

  Most UK fetal medicine centers agreed on using intravenous immunoglobulin to treat FNAIT, but opinions varied on when to begin treatment.

• No clear link found between signs of brain injury and IVH progression

  A study found brain injury and inflammation markers may not reliably reflect treatment progress for intraventricular hemorrhage (IVH).

• Clearer transfusion guidelines could improve care for pre-term infants

  A report of Canadian neonatal units showed there is wide variation in transfusion practices for pre-term babies.

• Case report: Newborn with rare dual diagnosis of FNAIT and HDFN

  A newborn survived a rare combination of Jka hemolytic disease,HDFN and FNAIT thanks to early diagnosis and aggressive treatment.

• New surgical plan may help infants recover from brain fluid buildup

  Hydrocephalus from fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be treated successfully with staged surgery, a review showed.

• Newborn with brain bleed and clot successfully treated with heparin

  In a recent case report, early use of heparin safely dissolved a life-threatening bleed and blood clot in the brain of a newborn.

• Pregnancies with blood disorders at greater risk of serious complications

  The study showed immune thrombocytopenia caused most maternal near-miss cases, especially when platelet counts dropped below 50×10⁹/L.

• Case report: Rare genetic mutation caused severe bleeding and FNAIT in infant

  A novel mutation, revealed by advanced genetic analysis, caused fetal and neonatal alloimmune thrombocytopenia (FNAIT) in a newborn.

• Potential FNAIT treatment approved for myasthenia gravis in US

  Nipocalimab’s success in gMG may bode well for its efficacy in treating FNAIT, a serious fetal condition with no approved therapies.